Preoperative CA-125 in low-grade endometrial cancer: risk stratification and implications for treatment

Janice S. Kwon

doi:10.3802/jgo.2019.30.e92

Although the majority of women with endometrial cancer are diagnosed with early stage low-risk disease and have an excellent prognosis, a small proportion of them have a poor outcome. Because of the global obesity epidemic, the incidence of endometrial cancer is increasing every year [1]. This will translate into more women who will recur and die of endometrial cancer. Identifying those at highest risk of recurrence is important in planning treatment.

In this issue, Reijnen et al. [2] report the outcomes of the PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, a prospective cohort study including women with endometrial cancer diagnosed at 9 hospitals in the Netherlands. All had preoperative cancer antigen 125 (CA-125) testing. CA-125 was elevated in 26.2% of women with low-grade (grade 1 or 2 endometrioid) endometrial cancer (EC), and almost 1 in 5 (19.4%) had a recurrence. The majority of these recurrences (73.7%) were distant. Elevated CA-125 was significantly associated with advanced International Federation of Gynecology and Obstetrics stage and deep myometrial invasion, and in the multivariable analysis adjusting for covariates, CA-125 was independently associated with both disease-free survival (DFS; hazard ratio [HR]=3.62; 95% confidence interval [CI]=2.15–6.09) and disease-specific survival (DSS; HR=4.18; 95% CI=2.26–7.72).

The majority of women with low-grade EC in this study did not have lymphadenectomy or lymph node sampling, including 92.7% and 77.8% with normal and elevated CA-125 levels, respectively. Preoperative elevated CA-125 is known to be associated with lymph node metastases [3 4 5 6 7]. Therefore, an elevated preoperative CA-125 in the context of low-grade EC might justify referral to a gynecologic oncologist for comprehensive surgical staging, including lymph node assessment. Preoperative computed tomography scan is insufficiently sensitive to detect occult nodal disease [8 9].

L1 cell adhesion molecule expression (L1CAM) [10 11] and p53 mutations or high-copy number alterations according to TCGA [12] are recognized for their association with adverse outcomes in endometrial cancer. It remains to be determined if these biomarkers can tailor treatment. Until then, CA-125 can be obtained on anyone diagnosed with endometrial cancer. Reijnen et al. [2] have demonstrated that CA-125 can identify those with low-grade endometrial cancer who are at high risk of recurrence, including distant metastases. Consideration should be given to surgical staging (which could include sentinel node biopsy rather than complete lymphadenectomy [13 14]) for those with an elevated CA-125, irrespective of preoperative grade.

Notes

^{Conflict of Interest} No potential conflict of interest relevant to this article was reported.

References

1. Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018; 6:e6–e15.

2. Reijnen C, Visser NC, Kasius JC, Boll D, Geomini PM, Ngo H, et al. Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study. J Gynecol Oncol. 2019; 30:e70.

3. Hsieh CH, ChangChien CC, Lin H, Huang EY, Huang CC, Lan KC, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002; 86:28–33.

4. Nicklin J, Janda M, Gebski V, Jobling T, Land R, Manolitsas T, et al. The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer. Int J Cancer. 2012; 131:885–890.

5. Scambia G, Gadducci A, Panici PB, Foti E, Ferdeghini M, Ferrandina G, et al. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol Oncol. 1994; 54:292–297.

6. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997; 90:441–447.

7. Yildiz A, Yetimalar H, Kasap B, Aydin C, Tatar S, Soylu F, et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2012; 164:191–195.

8. Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000; 95:692–696.

9. Zerbe MJ, Bristow R, Grumbine FC, Montz FJ. Inability of preoperative computed tomography scans to accurately predict the extent of myometrial invasion and extracorporal spread in endometrial cancer. Gynecol Oncol. 2000; 78:67–70.

10. van der Putten LJ, Visser NC, van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016; 115:716–724.

11. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013; 105:1142–1150.

12. Cancer Genome Atlas Research Network. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497:67–73.

13. Ducie JA, Eriksson AG, Ali N, McGree ME, Weaver AL, Bogani G, et al. Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecol Oncol. 2017; 147:541–548.

14. Zahl Eriksson AG, Ducie J, Ali N, McGree ME, Weaver AL, Bogani G, et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol Oncol. 2016; 140:394–399.